Hypo-fractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice.

CONCLUSION: The present results show that FLASH-RT delivered with hypo-fractionated regimens is able to spare the normal brain from radiation-induced toxicities without compromising tumor cure. This exciting capability provides an initial framework for future clinical applications of FLASH-RT.
PMID: 33060122 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 15, 2020 Category: Cancer & Oncology Authors: Montay-Gruel P, Acharya MM, Gonçalves Jorge P, Petit B, Petridis IG, Fuchs P, Leavitt R, Petersson K, Gondre M, Ollivier J, Moeckli R, Bochud F, Bailat C, Bourhis J, Germond JF, Limoli CL, Vozenin MC Tags: Clin Cancer Res Source Type: research